摘要
目的探讨早期尿激酶静脉溶栓治疗急性心肌梗死(AMI)的临床疗效及安全性。方法对25例AMI患者采用早期使用尿激酶栓治疗静脉再通溶栓治疗,并与25例AMI患者的常规治疗作对照。观察溶栓治疗患者的再通情况。结果尿激酶观察组与对照组的冠脉再通率分别为68.0%和16.0%,两组再通率差异有统计学意义(P<0.05);发病3 h内溶栓再通率(81.8%)明显高于3～6 h溶栓组、6～12 h内溶栓再通率(60.0%、25.0%),差异具有显著性(P<0.05)。结论早期尿激酶溶栓治疗可提高AMI患者冠脉再通率,降低病死率。
Objective To study the clinical efficacy and safety of early intravenous thrombolytic therapy with urokinase in treatment of patients with acute myocardial infarction.Methods Twenty five cases of AMI in observation group were treated with early application of intravenous thrombolytic therapy with urokinase for recanalization,and 25 cases of AMI in control group were treated with conventional therapy.The conditions of coronary recanalization in patients of these two groups were observed and compared.Results Rates of recanalization in coronary artery in patients of observation group and control group were 68% and 16% respectively,and the difference in recanalization rate between these two group was statistically significant（P0.05）between the two groups.The incidence of thrombolysis within 3 h reperfusion rate（81.8%） than thrombolysis group 3 ~ 6 h,6 ~ 12 h of thrombolytic recanalization rate（60.0%,25.0%）,the difference was significant（P0.05）.Conclusion Early thrombolytic therapy with urokinase is the key point for improving coronary artery recanalization rate of patients with acute myocardial infarction,thus it may reduce the mortality of patients with this disease.
出处
《临床和实验医学杂志》
2011年第12期906-907,共2页
Journal of Clinical and Experimental Medicine
关键词
急性心肌梗死
尿激酶
静脉溶栓
Acute myocardial infarction
Urokinase
Intravenous thrombolysis
